Presentation is loading. Please wait.

Presentation is loading. Please wait.

Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified.

Published byChristina Gundersen Modified over 5 years ago

Similar presentations

Presentation on theme: "Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified."— Presentation transcript:

1 Risk of having any adverse effects with supplements compared with placebo.
Risk of having any adverse effects with supplements compared with placebo. Stratified according to supplement. The order of supplements in the forest plots is to follow the effect size from small to large. The square data markers indicate the subtotal risk ratio (RR). The horizontal lines indicate 95%CIs. The diamond data markers represent overall RR and 95% CI. The solid vertical line shows the line of no effect (RR=1). Xiaoqian Liu et al. Br J Sports Med 2018;52: Copyright © BMJ Publishing Group Ltd & British Association of Sport and Exercise Medicine. All rights reserved.

Download ppt "Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified."

Similar presentations

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Influenza Vaccination and Cardiovascular.

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Influenza Vaccination and Cardiovascular.
Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved.
 Categorisation of direct and indirect admissions to the intensive care unit (ICU) from emergency departments (EDs), using source of admission.  Categorisation.

 Categorisation of direct and indirect admissions to the intensive care unit (ICU) from emergency departments (EDs), using source of admission.  Categorisation.
Attributable fractions (%) for all-cause deaths in 40 842 (3333 deaths) men and 12 943 (491 deaths) women in the Aerobics Center Longitudinal Study. Attributable.

Attributable fractions (%) for all-cause deaths in (3333 deaths) men and (491 deaths) women in the Aerobics Center Longitudinal Study. Attributable.
The Integrated Performance Health Management and Coaching Model.

The Integrated Performance Health Management and Coaching Model.
Ashish Shukla et al. JACEP 2015;1:41-51

Ashish Shukla et al. JACEP 2015;1:41-51
Bland-Altman plot comparing average steps/day over a 7-day period for the Fitbit tracker and ActiGraph accelerometer. Bland-Altman plot comparing average.

Bland-Altman plot comparing average steps/day over a 7-day period for the Fitbit tracker and ActiGraph accelerometer. Bland-Altman plot comparing average.
Bland-Altman plots comparing step counts over a 2 min walk test for the Fitbit tracker, ActiGraph accelerometer and visual count by a physiotherapist.

Bland-Altman plots comparing step counts over a 2 min walk test for the Fitbit tracker, ActiGraph accelerometer and visual count by a physiotherapist.
Flow chart of maternal, placental and fetal adaptations that occur in a low-risk pregnancy to protect the fetus from potential risks of maternal exercise.

Flow chart of maternal, placental and fetal adaptations that occur in a low-risk pregnancy to protect the fetus from potential risks of maternal exercise.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Yousef Rezaei, MD  American Journal of Kidney Diseases 

Yousef Rezaei, MD  American Journal of Kidney Diseases 
Effect of confidence interval reduction to demonstrate a true difference in means. Effect of confidence interval reduction to demonstrate a true difference.

Effect of confidence interval reduction to demonstrate a true difference in means. Effect of confidence interval reduction to demonstrate a true difference.
Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta- analysis of randomized placebo-controlled trials  E.M. Bartels,

Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta- analysis of randomized placebo-controlled trials  E.M. Bartels,
Subgroup analysis of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Subgroup analysis of the 17 trials comparing.

Subgroup analysis of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Subgroup analysis of the 17 trials comparing.
Funnel plot of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Funnel plot of the 17 trials comparing haloperidol.

Funnel plot of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Funnel plot of the 17 trials comparing haloperidol.
Longitudinal ultrasound image (A) of extensor carpi ulnaris tenosynovitis with prominent areas of anechoic fluid in the tendon sheath (white arrows). Longitudinal.

Longitudinal ultrasound image (A) of extensor carpi ulnaris tenosynovitis with prominent areas of anechoic fluid in the tendon sheath (white arrows). Longitudinal.
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.
Harvest plot of intervention effects on fitness and exercise capacity.

Harvest plot of intervention effects on fitness and exercise capacity.
Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.
Keratinocyte growth factor (KGF) versus no KGF for the reduction of severe oral mucositis in patients receiving treatment for cancer or undergoing haematopoietic.

Keratinocyte growth factor (KGF) versus no KGF for the reduction of severe oral mucositis in patients receiving treatment for cancer or undergoing haematopoietic.

Similar presentations

Ads by Google